|
1
|
Connor SJ, Hanna GB and Frizelle FA:
Appendiceal tumors: Retrospective clinicopathologic analysis of
appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum.
41:75–80. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McCusker ME, Coté TR, Clegg LX and Sobin
LH: Primary malignant neoplasms of the appendix: A population-based
study from the surveillance, epidemiology and end-results program,
1973–1998. Cancer. 94:3307–3312. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vukovic J, Vrebalov Cindro P, Tomic S and
Tonkic A: Signet ring carcinoma of the appendix presenting as
Crohn's disease in a young male. Case Rep Gastroenterol.
12:277–285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gagné F, Fortin P, Dufour V and Delage C:
Tumors of the appendix associating histologic features of carcinoid
and adenocarcinoma. Ann Anat Pathol (Paris). 14:393–406. 1969.(In
French). PubMed/NCBI
|
|
5
|
Pape UF, Perren A, Niederle B, Gross D,
Gress T, Costa F, Arnold R, Denecke T, Plöckinger U, Salazar R, et
al: ENETS consensus guidelines for the management of patients with
neuroendocrine neoplasms from the jejuno-ileum and the appendix
including goblet cell carcinomas. Neuroendocrinology. 95:135–156.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clift AK, Kornasiewicz O, Drymousis P,
Faiz O, Wasan HS, Kinross JM, Cecil T and Frilling A: Goblet cell
carcinomas of the appendix: Rare but aggressive neoplasms with
challenging management. Endocr Connect. 7:268–277. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Plöckinger U, Couvelard A, Falconi M,
Sundin A, Salazar R, Christ E, de Herder WW, Gross D, Knapp WH,
Knigge UP, et al: Consensus guidelines for the management of
patients with digestive neuroendocrine tumours: Well-differentiated
tumour/carcinoma of the appendix and goblet cell carcinoma.
Neuroendocrinology. 87:20–30. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND: WHO classification of tumours of the digestive
system4th. Intrenation agency for research on cancer; Lyon:
2010
|
|
9
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumoursJohn Wiley & Sons;
2011
|
|
10
|
Tang LH, Shia J, Soslow RA, Dhall D, Wong
WD, O'Reilly E, Qin J, Paty P, Weiser MR, Guillem J, et al:
Pathologic classification and clinical behavior of the spectrum of
goblet cell carcinoid tumors of the appendix. Am J Surg Pathol.
32:1429–1443. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee LH, McConnell YJ, Tsang E, Zerhouni S,
Speers C, Kennecke H and Schaeffer DF: Simplified 2-tier histologic
grading system accurately predicts outcomes in goblet cell
carcinoid of the appendix. Hum Pathol. 46:1881–1889. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yozu M, Johncilla ME, Srivastava A, Ryan
DP, Cusack JC, Doyle L, Setia N, Yang M, Lauwers GY, Odze RD and
Misdraji J: Histologic and outcome study supports reclassifying
appendiceal goblet cell carcinoids as goblet cell adenocarcinomas,
and grading and staging similarly to colonic adenocarcinomas. Am J
Surg Pathol. 42:898–910. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Boudreaux JP, Klimstra DS, Hassan MM,
Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL,
Caplin ME and Yao JC; North American Neuroendocrine Tumor Society
(NANETS), : The NANETS consensus guideline for the diagnosis and
management of neuroendocrine tumors: Well-differentiated
neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.
Pancreas. 39:753–766. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oberg K, Modlin IM, De Herder W, Pavel M,
Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg
J, et al: Consensus on biomarkers for neuroendocrine tumour
disease. Lancet Oncol. 16:e435–e446. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rindi G: The ENETS guidelines: The new TNM
classification system. Tumori J. 96:806–809. 2010. View Article : Google Scholar
|
|
16
|
Tsang ES, McConnell YJ, Schaeffer DF, Lee
L, Yin Y, Zerhouni S, Schaff K, Speers C and Kennecke HF: Outcomes
of surgical and chemotherapeutic treatments of goblet cell
carcinoid tumors of the appendix. Ann Surg Oncol. 25:2391–2399.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Madsen AH, Ladekarl M, Villadsen GE,
Grønbæk H, Sørensen MM, Stribolt K, Verwaal VJ and Iversen LH:
Effects of cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy (HIPEC) in the treatment of goblet cell carcinoma: A
prospective cohort study. Ann Surg Oncol. 25:422–430. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nonaka D, Papaxoinis G, Lamarca A, Fulford
P, Valle J and Chakrabarty B: A study of appendiceal crypt cell
adenocarcinoma (so-called goblet cell carcinoid and its related
adenocarcinoma). Hum Pathol. 72:18–27. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu HH, Yonemura Y, Hsieh MC, Mizumoto A,
Wakama S and Lu CY: Cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy for appendiceal goblet cell carcinomas
with peritoneal carcinomatosis: Results from a single specialized
center. Cancer Manag Res. 9:513–523. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gilmore G, Jensen K, Saligram S, Sachdev
TP and Arekapudi SR: Goblet cell carcinoid of the
appendix-diagnostic challenges and treatment updates: A case report
and review of the literature. J Med Case Rep. 12:2752018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lamarca A, Nonaka D, Lopez Escola C,
Hubner RA, O'Dwyer S, Chakrabarty B, Fulford P and Valle JW:
Appendiceal goblet cell carcinoids: Management considerations from
a reference peritoneal tumour service centre and ENETS centre of
excellence. Neuroendocrinology. 103:500–517. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Varisco B, McAlvin B, Dias J and Franga D:
Adenocarcinoid of the appendix: Is right hemicolectomy necessary? A
meta-analysis of retrospective chart reviews. Am Surg. 70:593–599.
2004.PubMed/NCBI
|
|
23
|
Nadler A, Cukier M, Rowsell C, Kamali S,
Feinberg Y, Singh S and Law CH: Ki-67 is a reliable pathological
grading marker for neuroendocrine tumors. Virchows Arch.
462:501–505. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jamali M and Chetty R: Predicting
prognosis in gastroentero-pancreatic neuroendocrine tumors: An
overview and the value of Ki-67 immunostaining. Endocr Pathol.
19:282–288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vilar E, Salazar R, Pérez-García J,
Cortes J, Öberg K and Tabernero J: Chemotherapy and role of the
proliferation marker Ki-67 in digestive neuroendocrine tumors.
Endocr Relat Cancer. 14:221–232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rorstad O: Prognostic indicators for
carcinoid neuroendocrine tumors of the gastrointestinal tract. J
Surg Oncol. 89:151–160. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu E, Telem DA, Warner RR, Dikman A and
Divino CM: The role of Ki-67 in predicting biological behavior of
goblet cell carcinoid tumor in appendix. Am J Surg. 202:400–403.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Taggart MW, Abraham SC, Overman MJ,
Mansfield PF and Rashid A: Goblet cell carcinoid tumor, mixed
goblet cell Carcinoid-Adenocarcinoma, and adenocarcinoma of the
appendix: Comparison of clinicopathologic features and prognosis.
Arch Pathol Lab Med. 139:782–790. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Burke AP, Sobin LH, Federspiel BH,
Shekitka KM and Helwig EB: Goblet cell carcinoids and related
tumors of the vermiform appendix. Am J Clin Pathol. 94:27–35. 1990.
View Article : Google Scholar : PubMed/NCBI
|
